The thyrotropin reference range should remain unchanged

被引:194
作者
Surks, MI
Goswami, G
Daniels, GH
机构
[1] Montefiore Med Ctr, Div Endocrinol & Metab, Dept Med, Bronx, NY 10467 USA
[2] Montefiore Med Ctr, Dept Pathol, Bronx, NY 10467 USA
[3] Albert Einstein Coll Med, Bronx, NY 10467 USA
[4] Massachusetts Gen Hosp, Thyroid Unit, Boston, MA 02114 USA
[5] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[6] Harvard Univ, Sch Med, Boston, MA 02114 USA
关键词
D O I
10.1210/jc.2005-0170
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Recent recommendations to decrease the upper limit of the TSH reference range from 4.5 to 2.5 mIU/liter, based on the high proportion of normal people whose serum TSH is less than 2.5 mIU/liter and the observation that those with TSH between 2.5 and 4.5 mIU/liter [upper reference range (URR)] have increased risk of progression to overt hypothyroidism (Whickham, 20-yr data), have not been subjected to critical analysis. Study Subjects: The study subjects were from the Reference Group of NHANES III, 14,333 people more than 12 yr old, without known thyroid disease or antithyroid antibodies; 85% had TSH levels below 2.5 mIU/liter, and 2.3% had subclinical hypothyroidism (SCH). An additional 9.7% had URR TSH, representing 20.6 million Americans, who would also be identified as SCH if the upper TSH limit were decreased. Many with URR TSH do not have thyroid disease. Intervention: The time of phlebotomy is important, because the TSH level varies throughout the day, with early morning values greater than later ones, and is accentuated by sleep deprivation, strenuous exercise, or working during the night or evening shifts. Repeated measurements in the same individual vary considerably over months. Results: About half of those with URR TSH probably have thyroid disease, but most with thyroid disease, antithyroid peroxidase antibodies, have TSH below 2.5 mIU/liter. Those with URR TSH with thyroid disease probably have minimal thyroid deficiency, without any reported adverse health consequences or benefit of treatments with levothyroxine. Conclusion: Because routine levothyroxine treatment is not recommended for SCH, it is certainly not warranted in individuals with URR TSH. For all patients with URR TSH, it is reasonable to determine serum TSH every 1-2 yr.
引用
收藏
页码:5489 / 5496
页数:8
相关论文
共 70 条
[1]   Germline mutations of TSH receptor gene as cause of nonautoimmune subclinical hypothyroidism [J].
Alberti, L ;
Proverbio, MC ;
Costagliola, S ;
Romoli, R ;
Boldrighini, B ;
Vigone, MC ;
Weber, G ;
Chiumello, G ;
Beck-Peccoz, P ;
Persani, L .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (06) :2549-2555
[2]  
Aldasouqi Saleh, 2004, Endocr Pract, V10, P399
[3]   Biologic variation is important for interpretation of thyroid function tests [J].
Andersen, S ;
Bruun, NH ;
Pedersen, KM ;
Laurberg, P .
THYROID, 2003, 13 (11) :1069-1078
[4]   Narrow individual variations in serum T4 and T3 in normal subjects:: A clue to the understanding of subclinical thyroid disease [J].
Andersen, S ;
Pedersen, KM ;
Bruun, NH ;
Laurberg, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (03) :1068-1072
[5]  
[Anonymous], 12 ANN M AM ASS CLIN
[6]   Subclinical hyperthyroidism as a risk factor for atrial fibrillation [J].
Auer, J ;
Scheibner, P ;
Mische, T ;
Langsteger, W ;
Eber, O ;
Eber, B .
AMERICAN HEART JOURNAL, 2001, 142 (05) :838-842
[7]   PLASMA THYROTROPIN, THYROXINE, AND TRIIODOTHYRONINE RELATIONSHIPS IN MAN [J].
AZUKIZAWA, M ;
PEKARY, AE ;
HERSHMAN, JM ;
PARKER, DC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1976, 43 (03) :533-542
[8]  
Baskin HJ., 2002, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, V8, P457, DOI DOI 10.4158/1934-2403-8.6.457
[9]   Risk for fracture in women with low serum levels of thyroid-stimulating hormone [J].
Bauer, DC ;
Ettinger, B ;
Nevitt, MC ;
Stone, KL .
ANNALS OF INTERNAL MEDICINE, 2001, 134 (07) :561-568
[10]   DECREASED RECEPTOR-BINDING OF BIOLOGICALLY INACTIVE THYROTROPIN IN CENTRAL HYPOTHYROIDISM - EFFECT OF TREATMENT WITH THYROTROPIN-RELEASING-HORMONE [J].
BECKPECCOZ, P ;
AMR, S ;
MENEZESFERREIRA, MM ;
FAGLIA, G ;
WEINTRAUB, BD .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (17) :1085-1090